GILD Stock Pops on COVID-19 Treatment Buzz

Gilead's remdesivir was lauded by President Trump last month as a promising COVID-19 treatment

by Lillian Currens

Published on Apr 6, 2020 at 10:18 AM

Gilead Sciences, Inc. (NASDAQ:GILD) is up 1% to trade at $79 this morning after the drugmaker said it plans on ramping up production on its experimental coronavirus treatment remdesivir, to 1 million treatment courses by the end of the year. Currently 1.5 million doses of the drug, or 140,000 treatment courses are available.

GILD has been outperforming the broad market for months now. U.S. President Donald Trump's comments last month touting Gilead's remdesivir treatment has undoubtedly helped put wind at the equity's back. Meanwhile, the stock's 60-day moving average has provided technical support on the charts. And while the $80 region, which is home to GILD's two-year closing high, has acted as a ceiling of late, GILD boasts a 20.4% year-to-date gain coming into today. 

Analysts remain split on the biotech name, with 11 calling it a "buy" or better, and 10 saying "hold" or worse. The consensus 12-month price target of $74.79 sits slightly below current levels. 

Analysts, on the other hand, have rarely been more bullish. This is per GILD's 50-day call/put volume ratio of 7.01 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 90% of all other readings from the past year. 


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Wall Street Reclaims Two Key Trendlines This Week
U.S.-China tensions and dire economic data still weigh, though
Dell Stock Jumps on Upbeat First Quarter
DELL announced an upbeat first-quarter report
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.